# A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

> **NCT07570017** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 42 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** Rocbrutinib
- **DRUG:** R-GemOx

## Key facts

- **NCT ID:** NCT07570017
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570017, "A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07570017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*